Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease

6Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Continuous drug delivery (CDD) has emerged as a feasible and pragmatic therapeutic option for dopamine replacement therapy in advanced Parkinson’s disease (PD). CDD aims to mimic the physiological tonic dopamine release from striatal dopaminergic neurons and thus reduces the severity and duration of motor and non-motor fluctuations partly related to pulsatile levodopa stimulation. Non-motor symptoms and fluctuations are ubiquitous in PD and include sleep dysfunction, a problem that occurs in over 90% of PD patients across all stages, from prodromal to palliative. In this review, we discuss the currently available and in development non-oral dopaminergic CDD strategies with a focus on their efficacy in the treatment of the burdensome sleep dysfunction in PD.

Cite

CITATION STYLE

APA

Tall, P., Qamar, M. A., Batzu, L., Leta, V., Falup-Pecurariu, C., & Ray Chaudhuri, K. (2023, November 1). Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease. Journal of Neural Transmission. Springer. https://doi.org/10.1007/s00702-023-02640-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free